High Drug Resistance in Feline Mammary Carcinoma Cell Line (FMCm) and Comparison with Human Breast Cancer Cell Line (MCF-7)

Abstract

Simple SummaryThe repurposing and combination of drugs are important therapeutic strategies in cancer therapy, being important for combating drug resistance and improving therapeutical regimens. This paper outlines the use of candidate drugs that are to be repurposed, and combines clinically approved drugs in breast cancer, aiming to understand the response of feline mammary carcinoma cells to this therapeutic approach, previously applied in human breast cancer cells. By using cell viability assays, we revealed that feline mammary carcinoma cells were highly resistant to these tested approaches, contrasting with human breast cancer cells.Drug repurposing and drug combination are important therapeutic approaches in cancer therapy. Drug repurposing aims to give new indications to drugs, rather than the original indication, whereas drug combination presupposes that the effect that is obtained should be more beneficial than the effect obtained by the individual drugs. Previously, drug repurposing and the combination of different drugs was evaluated in our research group against human breast cancer cells (MCF-7 cells). Our results demonstrated that the response obtained through the combination of drugs, when compared with the single drugs, led to more synergic responses. Therefore, using potential drugs for repurposing, combined with a reference drug in breast cancer (5-Fluorouracil), was the major aim of this project, but for the first time using the feline mammary carcinoma cell line, FMCm. Surprisingly, the feline neoplastic cells demonstrated considerable resistance to the drugs tested in isolation, and the combination was not effective, which contrasted with the obtained MCF-7 cells’ response.